BACKGROUND Little information has been published on the risks of cigar smoking.Since 1990 cigar smoking has become more prevalent in the United States.AIM To summarise the evidence from the United States relating excl...BACKGROUND Little information has been published on the risks of cigar smoking.Since 1990 cigar smoking has become more prevalent in the United States.AIM To summarise the evidence from the United States relating exclusive cigar smoking to risk of the major smoking-related diseases.METHODS Literature searches detected studies carried out in the United States which estimated the risk of lung cancer,chronic obstructive pulmonary disease(COPD),heart disease,stroke or overall circulatory disease in exclusive cigar smokers as compared to those who had never smoked any tobacco product.Papers were identified from reviews and detailed searches on MEDLINE.For each study,data were extracted onto a study database and a linked relative risk database.Relative risks and 95%CIs were extracted,or estimated,relating to current,former or ever exclusive cigar smokers,and meta-analysed using standard methods.Sensitivity analyses were conducted including or excluding results from studies that did not quite fit the full selection criteria(for example,a paper presenting combined results from five studies,where 86%of the population were in the United States).RESULTS The literature searches identified 17 relevant publications for lung cancer,four for COPD and 12 for heart disease,stroke and circulatory disease.These related to 11 studies for lung cancer,to four studies for COPD and to eight studies for heart disease,stroke or overall circulatory disease.As some studies provided results for more than one disease,the total number of studies considered was 13,with results from four of these used in sensitivity analyses.There was evidence of significant heterogeneity in some of the meta-analyses so the random-effects estimates are summarized below.As the results from the sensitivity analyses were generally very similar to those from the main analyses,and involved more data,only the sensitivity results are summarized below.For lung cancer,relative risks(95%CI)for current,former and ever smokers were respectively,2.98(2.08 to 4.26),1.61(1.23 to 2.09),and 2.22(1.79 to 2.74)based on 6,4 and 10 individual study estimates.For COPD,the corresponding estimates were 1.44(1.16 to 1.77),0.47(0.02 to 9.88),and 0.86(0.48 to 1.54)based on 4,2 and 2 estimates.For ischaemic heart disease(IHD)the estimates were 1.11(1.04 to 1.19),1.26(1.03 to 1.53)and 1.15(1.08 to 1.23)based on 6,3 and 4 estimates,while for stroke they were 1.02(0.92 to 1.13),1.08(0.85 to 1.38),and 1.11(0.95 to 1.31)based on 5,3 and 4 estimates.For overall circulatory disease they were 1.10(1.05 to 1.16),1.11(0.84 to 1.46),and 1.15(1.06 to 1.26)based on 3,3 and 4 estimates.CONCLUSION Exclusive cigar smoking is associated with an increased risk of lung cancer,and less so with COPD and IHD.The increases are lower than for cigarettes.展开更多
Background The Global Initiative for Chronic Obstructive Lung Disease （GOLD） presented a new ABCD group classification of chronic obstructive pulmonary disease （COPD）.We aimed to examine the association of spirome...Background The Global Initiative for Chronic Obstructive Lung Disease （GOLD） presented a new ABCD group classification of chronic obstructive pulmonary disease （COPD）.We aimed to examine the association of spirometric classification and the new GOLD classification with exacerbations,and to compare symptoms in different ways.Methods We investigated 848 patients with stable COPD from 24 hospitals.The annual frequencies of acute exacerbation and hospitalization were compared between the old and new classification.The symptom level was assessed using COPD assessment test （CAT） and modified British Medical Research Council （mMRC） questionnaire.Results A total of 848 patients were included in this study.According to spirometric classification,there were 32 patients of grade Ⅰ （3.8％）,315 of grade Ⅱ （37.1％）,366 of grade Ⅲ （43.2％）,and 135 of grade Ⅳ （15.9％）.According to GOLD 2011 classification,there were 59 patients of group A （7.0％）,172 of group B （20.3％）,55 of group C （6.5％）,and 562 of group D （66.3％）.In spirometric classification,the annual frequencies of acute exacerbation and associated hospitalization were respectively 1 （0-3） and 0 （0-2） for grade Ⅰ; 1 （0-5） and 0 （0-2） for grade Ⅱ; 2 （0-6） and 1 （0-3） for grade Ⅲ,and 3 （0-6） and 2 （0-3） for grade Ⅳ.In GOLD 2011,respectively 0 （0-3） and 0 （0-1） （group A）,1 （0-4） and 0 （0-3） （group B）,1 （0-5） and 0 （0-3） （group C）,and 3 （0-6） and 1 （0-3） （group D）.There were no significant difference between group B and C （Z=-1.347,P=0.178; Z=-0.772,P=0.440,respectively）.The coincidence rate using mMRC=1 and CAT=10 as cutoff points was 86.6％ （734/848,x=0.706）,compared with 77.9％ （661/848,K=0.60） using mMRC=2 and CAT=10.Conclusions Lung function test may be a better predictor of acute exacerbation and associated hospitalization of COPD.It is more appropriate to use mMRC=1 as cutoff point for assessing COPD symptoms.展开更多
Objective： To observe the clinical effect of acupuncture on chronic obstructive pulmonary disease （COPD）, and the improvements of patients＇ pulmonary ventilation function and 6-minute walk test （6-MWT） distance....Objective： To observe the clinical effect of acupuncture on chronic obstructive pulmonary disease （COPD）, and the improvements of patients＇ pulmonary ventilation function and 6-minute walk test （6-MWT） distance. Methods： A total of 80 COPD patients [grade 3-4 in Global Initiative for Chronic Obstructive Lung Disease （GOLD）, qi deficiency of the lung and kidney in traditional Chinese medicine （TCM） pattern] were randomly allocated into a treatment group （n=40） and a control group （n=40）. Salmeterol Xinafoate and Fluticasone Propionate powder （Seretide, 50 μg/250 μg） for inhalation was used for basic treatment in both groups （once in the morning and once in the evening）. Patients in the treatment group received acupuncture at Feishu （BL 13）, Shenshu （BL 23）, O.ihai （CV 6）, Guanyuan （CV 4）, Dingchuan （EX-B 1）, Danzhong （CV 17） and Zusanli （ST 36] twice a week for 3 months. After 3 months of treatment, clinical effects, lung ventilation functions and 6-MWT distance were observed and compared in the two groups. Results： After 3 months of treatment, the total effective rate was 95.0% in the treatment group, versus 80.0% in the control group, showing a statistical difference （P〈O.05）; the phlegm expectoration, dyspnea and shortness of breath were more significantly improved in the treatment group than those in the control group （P〈0.01, P〈0.05）; and the 6-MWT distance and forced expiratory volume in 1 second percentage of predicted value （FEV1%） were more significantly improved in the treatment group than those in the control group （P〈0.05, P〈0.01）. Conclusion： Seretide inhaler combined with acupuncture can improve signs and symptoms in COPD patients, increase the 6-MWT distance, imorove FEV1% and obtain better results than Seretide alone.展开更多
背景与目的肺癌是慢性阻塞性肺疾病(慢阻肺)重要的合并症,会显著影响慢阻肺患者的预后。慢阻肺也会影响肺癌患者的术后并发症和复发。本研究旨在调查胸外科住院肺癌合并慢阻肺的情况。方法回顾性分析北京大学人民医院胸外科2015年1月-2...背景与目的肺癌是慢性阻塞性肺疾病(慢阻肺)重要的合并症,会显著影响慢阻肺患者的预后。慢阻肺也会影响肺癌患者的术后并发症和复发。本研究旨在调查胸外科住院肺癌合并慢阻肺的情况。方法回顾性分析北京大学人民医院胸外科2015年1月-2015年12月收治的原发性非小细胞肺癌患者。通过查阅病历获取患者的性别、年龄、吸烟状况、有害职业史、症状、胸部计算机断层扫描(computed tomography,CT)、术后病理、出院诊断、全套肺功能及支气管舒张试验,当基础肺功能第一秒钟用力呼气容积(forced expiratory volume in one second,FEV_1)占预计值<70%时即行支气管舒张试验。结果 703例肺癌患者进行了全套肺功能测定,其中67例进行支气管舒张试验,62例(92.5%)符合慢阻肺诊断。接受手术治疗的肺癌患者有677例,其中41例进行支气管舒张试验,38例(92.7%)符合慢阻肺诊断。在接受手术治疗的肺癌患者中合并慢阻肺者年龄≥65岁、男性、有吸烟史和非腺癌的比例高于未合并慢阻肺者,差异有统计学意义(P<0.05);男性和≥65岁者更易合并慢阻肺(OR:2.807-2.374,95%CI:1.101-7.157)(P<0.05)。住院前仅有3例(4.3‰)诊断慢阻肺并按慢阻肺规范治疗。出院时仅有5例(7.1‰)诊断慢阻肺。结论在胸外科住院肺癌患者中行常规肺功能及支气管舒张试验可提高肺癌合并慢阻肺的诊断;当前肺癌合并慢阻肺诊断和治疗严重不足,需要引起胸外科医生重视,与呼吸内科医生携手共同防治慢阻肺。展开更多
基金Supported by the JT International SA,Assignment Schedule,No.14.
文摘BACKGROUND Little information has been published on the risks of cigar smoking.Since 1990 cigar smoking has become more prevalent in the United States.AIM To summarise the evidence from the United States relating exclusive cigar smoking to risk of the major smoking-related diseases.METHODS Literature searches detected studies carried out in the United States which estimated the risk of lung cancer,chronic obstructive pulmonary disease(COPD),heart disease,stroke or overall circulatory disease in exclusive cigar smokers as compared to those who had never smoked any tobacco product.Papers were identified from reviews and detailed searches on MEDLINE.For each study,data were extracted onto a study database and a linked relative risk database.Relative risks and 95%CIs were extracted,or estimated,relating to current,former or ever exclusive cigar smokers,and meta-analysed using standard methods.Sensitivity analyses were conducted including or excluding results from studies that did not quite fit the full selection criteria(for example,a paper presenting combined results from five studies,where 86%of the population were in the United States).RESULTS The literature searches identified 17 relevant publications for lung cancer,four for COPD and 12 for heart disease,stroke and circulatory disease.These related to 11 studies for lung cancer,to four studies for COPD and to eight studies for heart disease,stroke or overall circulatory disease.As some studies provided results for more than one disease,the total number of studies considered was 13,with results from four of these used in sensitivity analyses.There was evidence of significant heterogeneity in some of the meta-analyses so the random-effects estimates are summarized below.As the results from the sensitivity analyses were generally very similar to those from the main analyses,and involved more data,only the sensitivity results are summarized below.For lung cancer,relative risks(95%CI)for current,former and ever smokers were respectively,2.98(2.08 to 4.26),1.61(1.23 to 2.09),and 2.22(1.79 to 2.74)based on 6,4 and 10 individual study estimates.For COPD,the corresponding estimates were 1.44(1.16 to 1.77),0.47(0.02 to 9.88),and 0.86(0.48 to 1.54)based on 4,2 and 2 estimates.For ischaemic heart disease(IHD)the estimates were 1.11(1.04 to 1.19),1.26(1.03 to 1.53)and 1.15(1.08 to 1.23)based on 6,3 and 4 estimates,while for stroke they were 1.02(0.92 to 1.13),1.08(0.85 to 1.38),and 1.11(0.95 to 1.31)based on 5,3 and 4 estimates.For overall circulatory disease they were 1.10(1.05 to 1.16),1.11(0.84 to 1.46),and 1.15(1.06 to 1.26)based on 3,3 and 4 estimates.CONCLUSION Exclusive cigar smoking is associated with an increased risk of lung cancer,and less so with COPD and IHD.The increases are lower than for cigarettes.
文摘Background The Global Initiative for Chronic Obstructive Lung Disease （GOLD） presented a new ABCD group classification of chronic obstructive pulmonary disease （COPD）.We aimed to examine the association of spirometric classification and the new GOLD classification with exacerbations,and to compare symptoms in different ways.Methods We investigated 848 patients with stable COPD from 24 hospitals.The annual frequencies of acute exacerbation and hospitalization were compared between the old and new classification.The symptom level was assessed using COPD assessment test （CAT） and modified British Medical Research Council （mMRC） questionnaire.Results A total of 848 patients were included in this study.According to spirometric classification,there were 32 patients of grade Ⅰ （3.8％）,315 of grade Ⅱ （37.1％）,366 of grade Ⅲ （43.2％）,and 135 of grade Ⅳ （15.9％）.According to GOLD 2011 classification,there were 59 patients of group A （7.0％）,172 of group B （20.3％）,55 of group C （6.5％）,and 562 of group D （66.3％）.In spirometric classification,the annual frequencies of acute exacerbation and associated hospitalization were respectively 1 （0-3） and 0 （0-2） for grade Ⅰ; 1 （0-5） and 0 （0-2） for grade Ⅱ; 2 （0-6） and 1 （0-3） for grade Ⅲ,and 3 （0-6） and 2 （0-3） for grade Ⅳ.In GOLD 2011,respectively 0 （0-3） and 0 （0-1） （group A）,1 （0-4） and 0 （0-3） （group B）,1 （0-5） and 0 （0-3） （group C）,and 3 （0-6） and 1 （0-3） （group D）.There were no significant difference between group B and C （Z=-1.347,P=0.178; Z=-0.772,P=0.440,respectively）.The coincidence rate using mMRC=1 and CAT=10 as cutoff points was 86.6％ （734/848,x=0.706）,compared with 77.9％ （661/848,K=0.60） using mMRC=2 and CAT=10.Conclusions Lung function test may be a better predictor of acute exacerbation and associated hospitalization of COPD.It is more appropriate to use mMRC=1 as cutoff point for assessing COPD symptoms.
基金supported by Shanghai Key Laboratory for Clinical Chinese Medicine~~
文摘Objective： To observe the clinical effect of acupuncture on chronic obstructive pulmonary disease （COPD）, and the improvements of patients＇ pulmonary ventilation function and 6-minute walk test （6-MWT） distance. Methods： A total of 80 COPD patients [grade 3-4 in Global Initiative for Chronic Obstructive Lung Disease （GOLD）, qi deficiency of the lung and kidney in traditional Chinese medicine （TCM） pattern] were randomly allocated into a treatment group （n=40） and a control group （n=40）. Salmeterol Xinafoate and Fluticasone Propionate powder （Seretide, 50 μg/250 μg） for inhalation was used for basic treatment in both groups （once in the morning and once in the evening）. Patients in the treatment group received acupuncture at Feishu （BL 13）, Shenshu （BL 23）, O.ihai （CV 6）, Guanyuan （CV 4）, Dingchuan （EX-B 1）, Danzhong （CV 17） and Zusanli （ST 36] twice a week for 3 months. After 3 months of treatment, clinical effects, lung ventilation functions and 6-MWT distance were observed and compared in the two groups. Results： After 3 months of treatment, the total effective rate was 95.0% in the treatment group, versus 80.0% in the control group, showing a statistical difference （P〈O.05）; the phlegm expectoration, dyspnea and shortness of breath were more significantly improved in the treatment group than those in the control group （P〈0.01, P〈0.05）; and the 6-MWT distance and forced expiratory volume in 1 second percentage of predicted value （FEV1%） were more significantly improved in the treatment group than those in the control group （P〈0.05, P〈0.01）. Conclusion： Seretide inhaler combined with acupuncture can improve signs and symptoms in COPD patients, increase the 6-MWT distance, imorove FEV1% and obtain better results than Seretide alone.
文摘背景与目的肺癌是慢性阻塞性肺疾病(慢阻肺)重要的合并症,会显著影响慢阻肺患者的预后。慢阻肺也会影响肺癌患者的术后并发症和复发。本研究旨在调查胸外科住院肺癌合并慢阻肺的情况。方法回顾性分析北京大学人民医院胸外科2015年1月-2015年12月收治的原发性非小细胞肺癌患者。通过查阅病历获取患者的性别、年龄、吸烟状况、有害职业史、症状、胸部计算机断层扫描(computed tomography,CT)、术后病理、出院诊断、全套肺功能及支气管舒张试验,当基础肺功能第一秒钟用力呼气容积(forced expiratory volume in one second,FEV_1)占预计值<70%时即行支气管舒张试验。结果 703例肺癌患者进行了全套肺功能测定,其中67例进行支气管舒张试验,62例(92.5%)符合慢阻肺诊断。接受手术治疗的肺癌患者有677例,其中41例进行支气管舒张试验,38例(92.7%)符合慢阻肺诊断。在接受手术治疗的肺癌患者中合并慢阻肺者年龄≥65岁、男性、有吸烟史和非腺癌的比例高于未合并慢阻肺者,差异有统计学意义(P<0.05);男性和≥65岁者更易合并慢阻肺(OR:2.807-2.374,95%CI:1.101-7.157)(P<0.05)。住院前仅有3例(4.3‰)诊断慢阻肺并按慢阻肺规范治疗。出院时仅有5例(7.1‰)诊断慢阻肺。结论在胸外科住院肺癌患者中行常规肺功能及支气管舒张试验可提高肺癌合并慢阻肺的诊断;当前肺癌合并慢阻肺诊断和治疗严重不足,需要引起胸外科医生重视,与呼吸内科医生携手共同防治慢阻肺。
